



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 19/08/2011.

Umme Salma
Assistant Director,
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT AND INDUSTRIAL DESIGNS
FOR THE WEEK-ENDING OF 13/08/2011 TO BE PUBLISHED. IN
THE 23/08/2011 GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Sabir Gul)
Controller of Patents
& Registrar of Designs
Ph: 99215056

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

08-08-2011

581/2011	Glaxo Group Limited United Kingdom (Priority 10-08-2010 USA)	“Quinolyl amines as kinase inhibitors”
582/2011	Dr. Ishtiaq Qadri and Dr. Kaneez Fatima Pakistan	“Construction and Purification of HCV NS3 recombinant Single Chain serine Protease with NS4a peptide of Genotype 3a from Pakistani Population”
583/2011	Dr. Ishtiaq Qadri and Dr. Kaneez Fatima Pakistan	“Development of robust in vitro FRET based assay for recombinant Pakistani HCV NS3-4A protease”

09-08-2011

584/2011	Novacem Limited United Kingdom (Priority 02-09-2010 UK)	“Binder composition”
585/2011	Sanofi France (Priority 14-12-2009 France) Divisional	“Pharmaceutically acceptable salt of (heterocycle-tetrahydropyridine) (piperazinyl)-1-alkanone and (heterocycle-dihydropyrrolidine) (piperazinyl)-1-alkanone derivative”
586/2011	Takeda Pharmaceutical Company Limited Japan (Priority 10-08-2010 USA)	“Heterocyclic compound and use thereof”
587/2011	Unilever Plc United Kingdom (Priority 24-08-2010 India)	“A water purification device ”
588/2011	Council Of Scientific & Industrial Research India	“Protein fusion constructs possessing thrombolytic and anticoagulant properties”

10-08-2011

589/2011	Dr. Suhail Zaki Farooqui Pakistan	“The Juggler's Drum Knee Separator”
590/2011	Sanofi France (Priority 09-04-2009 France) Divisional	“Pharmaceutically acceptable salt of a substituted quinazolinone compounds for the treatment of cardiovascular diseases”
591/2011	Sanofi France (Priority 12-08-2010 EP)	“Process for the preparation of enantiomeric forms of 2,3-aminopropionic acid derivatives”
592/2011	Takeda Pharmaceutical Company Limited Japan	“Heterocyclic Compounds”
593/2011	Golden Biotechnology Corporation Taiwan (Priority 20-09-2010 Taiwan)	“Methods and compositions for treating lung cancer”
594/2011	Millennium Pharmaceuticals, INC. USA (Priority 11-08-2010 USA) (Priority 11-08-2010 USA)	“Heteroaryls and uses thereof”
595/2011	Boehringer Ingelheim International GmbH Germany (Priority 12-08-2010 EP)	“6-Cycloalkyl-pyrazolopyrimidinones for the Treatment of CNS Disorders”
596/2011	Merck Sharp & Dohme Corp USA (Priority 16-08-2010 USA)	“Process for preparing aminocyclohexyl ether compounds”

11-08-2011

597/2011	Millennium Pharmaceuticals, Inc USA (Priority 11-08-2010 USA)	“Heteroaryls and uses thereof”
----------	---	--------------------------------

12-08-2011

- | | | |
|----------|--|--|
| 598/2011 | Dolby Laboratories Licensing Corporation USA and DOLBY INTERNATIONAL AB
Netherlands | “Audio decoder and decoding method using efficient downmixing” |
| 599/2011 | Boehringer Ingelheim International GmbH
Germany
(Priority 16-08-2010 USA) | “Oxadiazole inhibitors of leukotriene production” |

13-08-2011

- | | | |
|----------|--|--|
| 600/2011 | Jose Raimundo Filho
Brazil
(Priority 13-08-2010 USA) | “Method and composition for producing clarified sugar” |
|----------|--|--|

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


267/2002 Pfizer INC.
USA

“4-phenoxy pyrazole compound”

C07D 231/12

141225

This invention relates to pyrazole compound of formula (I)



wherein R1 to R4 are defined in the description, composition containing them and the use of the compound.

The compound of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compound of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

298/2007

Farzana Azmat
Muhammad Adil.
Syed Mohsin Ali
Pakistan

“A process for the production of magnesium chloride from sea bittern”

C07D /00

141226

Sea Bittern, the mother liquor left after recovery of sodium chloride, a waste product of salt industry, is a potential source of magnesium compounds.

A process has been developed to produce magnesium chloride ($MgCl_2 \cdot 6H_2O$). Sea bittern contains magnesium salt in the form of chloride and sulphate, which is desulphated from calcium chloride to convert magnesium sulphate into magnesium chloride and calcium sulphate which is filtered off and filtrate is concentrated to a specific density resulting in crystalline magnesium chloride hexa hydrate ($MgCl_2 \cdot 6H_2O$).

1226/2007


SGX Pharmaceuticals, INC.
USA



“Bicyclic triazole compound as protein kinase modulator”

C07D 487/04, A61P 31/00.

141227

A compound having formula:





1475/07


Pfizer INC
USA

“Pharmaceutically acceptable salt of 4-
phenoxyprazole compound”

A61K 31/415, A61P 31/18, C07D 231/18.

141228

This invention relates to pharmaceutically
acceptable salt of compound of formula (I)



wherein R1 to R4 are defined in the description,
and to process for the preparation thereof,
composition containing them and their use.

The pharmaceutically acceptable salt of compound
of the present invention bind to the enzyme reverse
transcriptase and are modulators, especially
inhibitors thereof. As such the compound of the
present invention are useful in the treatment of a
variety of disorders including those in which the
inhibition of reverse transcriptase is implicated.
Disorders of interest include those caused by
Human Immunodeficiency Virus (HIV) and
genetically related retroviruses, such as Acquired
Immune Deficiency Syndrome (AIDS).

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Inventor
<u>08-08-2011</u>			
1	15855	Chappals (Class-06)	Swiss Boot House
2	15856	Chappals (Class-06)	Swiss Boot House
3	15857	Ice Cream or Ice Block (Class-12)	Nigel John Keats
<u>09-08-2011</u>			
4	15858	Football (Class-06)	Laser Sports (Pvt.) Ltd
<u>12-08-2011</u>			
5	15859	Packaging (Class-03)	Koninklijke Philips Electronics N.V.

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No.	Design No.	Title & Class	Inventor
<u>09-08-2011</u>			
1	15556	Hydro Crimping Machine (Class- 01)	M/s. Khalil Industry

(SABIR GUL)
Controller of Patents
& Registrar of Designs
Ph: 99215056